JP2008500999A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008500999A5 JP2008500999A5 JP2007513941A JP2007513941A JP2008500999A5 JP 2008500999 A5 JP2008500999 A5 JP 2008500999A5 JP 2007513941 A JP2007513941 A JP 2007513941A JP 2007513941 A JP2007513941 A JP 2007513941A JP 2008500999 A5 JP2008500999 A5 JP 2008500999A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylcarbonyl
- compound
- halogen
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 230000007170 pathology Effects 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- -1 benzoimidazolyl Chemical group 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 150000003254 radicals Chemical class 0.000 claims 5
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000002971 oxazolyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims 2
- 206010020571 Hyperaldosteronism Diseases 0.000 claims 2
- 125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 229960000890 hydrocortisone Drugs 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000000297 inotrophic effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 0 C*1C*(*C(*)(*NC2)C3CCCCCC3)N2C(*)(*)CC1 Chemical compound C*1C*(*C(*)(*NC2)C3CCCCCC3)N2C(*)(*)CC1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH9162004 | 2004-05-28 | ||
| CH11572004 | 2004-07-09 | ||
| PCT/EP2005/052418 WO2005118541A2 (en) | 2004-05-28 | 2005-05-27 | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008500999A JP2008500999A (ja) | 2008-01-17 |
| JP2008500999A5 true JP2008500999A5 (enExample) | 2008-07-10 |
Family
ID=34993240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007513941A Pending JP2008500999A (ja) | 2004-05-28 | 2005-05-27 | 複素環式化合物およびアルドステロンシンターゼ阻害薬としてのそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20080076794A1 (enExample) |
| EP (1) | EP1748986B1 (enExample) |
| JP (1) | JP2008500999A (enExample) |
| AR (1) | AR050251A1 (enExample) |
| AT (1) | ATE490241T1 (enExample) |
| BR (1) | BRPI0510412A (enExample) |
| CA (1) | CA2568164A1 (enExample) |
| DE (1) | DE602005025110D1 (enExample) |
| IL (1) | IL179409A0 (enExample) |
| TW (1) | TW200608978A (enExample) |
| WO (1) | WO2005118541A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200616623A (en) * | 2004-05-28 | 2006-06-01 | Speedel Experimenta Ag | Organic compounds |
| TW200716105A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
| TW200804378A (en) * | 2005-12-09 | 2008-01-16 | Speedel Experimenta Ag | Organic compounds |
| EP1842543A1 (en) | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
| TW200808812A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| EP1886695A1 (en) * | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
| JP5420761B2 (ja) | 2009-05-28 | 2014-02-19 | ノバルティス アーゲー | ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体 |
| KR20120041702A (ko) | 2009-05-28 | 2012-05-02 | 노파르티스 아게 | 네프릴리신 억제제로서의 치환된 아미노부티르산 유도체 |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| TWI627167B (zh) | 2011-07-08 | 2018-06-21 | 諾華公司 | 用於高三酸甘油酯個體治療動脈粥狀硬化之方法 |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| WO2014126979A1 (en) | 2013-02-14 | 2014-08-21 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors |
| CA2918074A1 (en) | 2013-07-25 | 2015-01-29 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
| CA2918077A1 (en) | 2013-07-25 | 2015-01-29 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
| AU2016209968B2 (en) | 2015-01-23 | 2018-11-29 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| WO2020110011A1 (en) | 2018-11-27 | 2020-06-04 | Novartis Ag | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| US20230089867A1 (en) | 2018-11-27 | 2023-03-23 | Novartis Ag | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
| WO2023084449A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
| AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
| WO2024241229A1 (en) | 2023-05-24 | 2024-11-28 | Novartis Ag | Naphthyridinone derivatives for the treatment of a disease or disorder |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4859691A (en) * | 1987-07-08 | 1989-08-22 | Ciba-Geigy Corporation | Certain 1,2-benzisoxazole derivatives |
| GB8820730D0 (en) * | 1988-09-02 | 1988-10-05 | Erba Carlo Spa | Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation |
| US5057521A (en) * | 1988-10-26 | 1991-10-15 | Ciba-Geigy Corporation | Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism |
| JP3170273B2 (ja) * | 1989-06-05 | 2001-05-28 | 第一製薬株式会社 | 縮合トリアジン誘導体及びその中間体 |
| EP0401707B1 (en) * | 1989-06-05 | 1994-09-21 | Daiichi Pharmaceutical Co., Ltd. | Heterocyclic triazin or triazolo compounds having serotonin 2-receptor antagonistic activity |
| CA2026792A1 (en) * | 1989-11-01 | 1991-05-02 | Michael N. Greco | (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives |
| DK0625155T3 (da) * | 1992-01-27 | 2001-11-12 | Janssen Pharmaceutica Nv | Pyrroloimidazolyl- og imidazopyridinyl-substituerede 1H-benzimidazolderivater som aromataseinhibitorer |
| JPH0971586A (ja) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | 新規な二環性縮合イミダゾール誘導体 |
| WO2002102250A1 (en) * | 1999-10-22 | 2002-12-27 | Glaxo Group Limited | $g(in vivo) imaging |
| US20030083342A1 (en) * | 2002-08-27 | 2003-05-01 | Steele Ronald Edward | Combination of organic compounds |
-
2005
- 2005-05-27 TW TW094117479A patent/TW200608978A/zh unknown
- 2005-05-27 AT AT05749325T patent/ATE490241T1/de not_active IP Right Cessation
- 2005-05-27 AR ARP050102198A patent/AR050251A1/es unknown
- 2005-05-27 JP JP2007513941A patent/JP2008500999A/ja active Pending
- 2005-05-27 WO PCT/EP2005/052418 patent/WO2005118541A2/en not_active Ceased
- 2005-05-27 EP EP05749325A patent/EP1748986B1/en not_active Expired - Lifetime
- 2005-05-27 US US11/597,615 patent/US20080076794A1/en not_active Abandoned
- 2005-05-27 DE DE602005025110T patent/DE602005025110D1/de not_active Expired - Fee Related
- 2005-05-27 BR BRPI0510412-2A patent/BRPI0510412A/pt not_active IP Right Cessation
- 2005-05-27 CA CA002568164A patent/CA2568164A1/en not_active Abandoned
-
2006
- 2006-11-20 IL IL179409A patent/IL179409A0/en unknown